SLAM
IOVA icon

Swiss Life Asset Management’s Iovance Biotherapeutics IOVA Stock Holding History

Swiss Life Asset Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$83.6K Buy
20,086
+3,332
+20% +$12.7K ﹤0.01% 1604
2026
Q1 		$58.8K Buy
16,754
+3,487
+26% +$11.2K ﹤0.01% 1484
2025
Q4 		$36.2K Buy
13,267
+2,190
+20% +$5.07K ﹤0.01% 1370
2025
Q3 		$24K Buy
+11,077
New +$26.2K ﹤0.01% 1189

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
OIC
Orion Investment Company St. Louis, Missouri $343M AUM 52.59% 1-Year Est. Return
DMKJ
David M. Knott Jr $189M AUM 67.72% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Swiss Life Asset Management's IOVA Position: Q2 2026 in Review

Swiss Life Asset Management increased its Iovance Biotherapeutics (IOVA) stake by 20% in Q2 2026, buying an estimated $12.7K and bringing the position to 20,086 shares worth $83.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1604.

Swiss Life Asset Management first reported a position in IOVA in Q3 2025 and has held it in 4 quarters since. 171 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Swiss Life Asset Management held 20,086 shares of Iovance Biotherapeutics worth $83.6K as of Q2 2026.
  • Swiss Life Asset Management bought 3,332 Iovance Biotherapeutics shares in Q2 2026, an estimated $12.7K.
  • Iovance Biotherapeutics made up ﹤0.01% of Swiss Life Asset Management's portfolio in Q2 2026, its #1604 holding.
  • Swiss Life Asset Management first reported a position in Iovance Biotherapeutics in Q3 2025 and has held it in 4 quarters since.
  • 171 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Swiss Life Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.